Management of Hepatitis B Infection

  • Authors: Harry L. A. Janssen, MD, PhD; Milan J. Sonneveld, MD, PhD, MSc (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 5/25/18 (What's New)

Summary

  • In the United States, lamivudine is indicated for the treatment of compensated chronic HBV infection associated with hepatitis B viral replication, if other agents with a higher barrier of resistance cannot be used (Table 3)[FDA Lamivudine]
  • The European indication includes patients with decompensated liver disease[EMA Lamivudine]
  • A high rate of resistance precludes use of lamivudine as a first-line HBV agent

Action required